Даптомицин: обзор фармакологических, клинических и микробиологических параметров | КМАХ

Даптомицин: обзор фармакологических, клинических и микробиологических параметров

Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(4):295-313

​ Дехнич А.В., Данилов А.И.
даптомицин липопептиды антибиотикорезистентность инфекции кожи и мягких тканей бактериемия эндокардит S. aureus Enterococcus spp
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(4):295-313

Аннотация

Даптомицин является первым и единственным дошедшим до клинического применения представителем класса циклических полипептидов, активных в отношении грам(+) микроорганизмов. В отличие от большинства других антибиотиков, он обладает быстрой бактерицидной активностью, в том числе в отношении медленно делящихся микробных клеток и микробных клеток в составе биопленок. В спектр активности даптомицина входят практически все клинически значимые грам(+) бактерии, включая штаммы, устойчивые к другим классам антимикробных препаратов. На настоящий момент даптомицин зарегистрирован по двум показаниям — осложненные инфекции кожи и мягких тканей в дозе 4 мг/кг 1 раз в сутки и инфекции кровотока, вызванные S. aureus, включая бактериемию и правосторонний эндокардит, в дозе 6 мг/кг 1 раз в сутки. Но есть многочисленные исследования и наблюдения, показывающие потенциальную возможность использования даптомицина и при ряде других заболеваний, таких как инфекции костей и суставов, фебрильная нейтропения и др., вызванных полирезистентными грам(+) штаммами. Учитывая клинико-фармакологический и микробиологический профиль препарата, а также ситуацию с антибиотикорезистентностью грам(+) возбудителей в России, даптомицин однозначно должен занять одно из важных мест в антибиотикотерапии в стационарах нашей страны.

  • 1. Raja A., LaBonte J., Lebbos J., Kirkpatrick P. Daptomycin. Nature Reviews Drug Discovery 2003; 2:943-4.
  • 2. Bryskier A. Peptide antibiotics. In: Bryskier A. editor, Antimicrobial Agents. ASM Press: Washington DC, USA. 2005. p. 826-79.
  • 3. Eliopoulos GM, Thauvin C, Gerson B et al. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 1985; 27:357-62.
  • 4. Tally F.P., DeBruin M.F: Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000; 46:523-26.
  • 5. Rybak M.J., Bailey E.M., Lamp K.C., Kaatz G.W. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992; 36:1109-14.
  • 6. Oleson F.B., Berman C.L., Kirkpatrick J.B., Regan K.S., Lai J.J., Tally F.P. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948-53.
  • 7. Sauermann R., Rothenburger M., Graninger W., Joukhadar C. Daptomycin: A review 4 years after first approval. Pharmacology 2008; 81:79-91.
  • 8. Miao V., Coëffet-Legal M.F., Brian P. Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 2005; 151:1507-23.
  • 9. Allen N.E., Alborn W.E., Hobbs J.N. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991; 35:2639-42.
  • 10. Silverman J.A., Perlmutter N.G., Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:2538-44.
  • 11. Jung D., Rozek A., Okon M., Hancock R.E. Structural transitions as determinants of the action of the calciumdependent antibiotic daptomycin. Chem Biol 2004; 11:949-57.
  • 12. Jung D., Rozek A., Okon M., et al. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 2004; 11:949-57.
  • 13. Hanberger H., Nilsson L.E., Maller R., Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-6.
  • 14. Alborn W.E., Allen N.E., Preston D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35:2282-7.
  • 15. Lamp K.C., Rybak M.J., Bailey E.M., Kaatz G.W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992; 36:2709-14.
  • 16. Cubicin prescribing information. Cubist Pharmaceuticals. Lexington, MA; 2008.
  • 17. Pfaller M.A., Sader H.S., Jones R.N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbial Infect Dis 2007; 57:459-65.
  • 18. Streit J.M., Jones R.N., Sader H.S. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Grampositive organisms. J Antimicrob Chemother 2004; 53:669-74.
  • 19. Critchley I.A., Draghi D.C., Sahm D.F., Thornsberry C., Jones M.E., Karlowsky J.A. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003; 51:639-49.
  • 20. Koeth L.M., Thorne G.M. Daptomycin in vitro susceptibility methodology: a review of methods, including determination of calcium in testing media. Clinical Microbiology Newsletter 2010; 32:161-9.
  • 21. Piper K.E., Steckelberg J.M., Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. J Infect Chemother 2005; 11:207-9.
  • 22. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H.T. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004; 48:2149-52.
  • 23. Safdar N., Andes D., Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63-8.
  • 24. Louie A., Kaw P., Liu W., Jumbe N., Miller M.H., Drusano G.L. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45:845-51.
  • 25. Woodworth J.R., Nyhart E.H., Brier G.L., Wolny J.D., Black H.R. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36:318-25.
  • 26. Lee B.L., Sachdeva M., Chambers H.F. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother 1991; 35:2505-8.
  • 27. Garrison M.W., Vance-Bryan K., Larson T.A., Toscano J.P., Rotschafer J.C. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1990; 34:1925-31.
  • 28. Pankuch G.A., Jacobs M.R., Appelbaum P.C. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother 2003; 47:3012-4.
  • 29. Raad I., Hanna H., Jiang Y., Dvorak T., Reitzel R., et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillinresistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656-60.
  • 30. Edmiston C.E., Goheen M.P., Seabrook G.R., et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006; 192:344-54.
  • 31. Laplante K.L., Mermel L.A. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239-46.
  • 32. Raad I., Hanna H.A., Boktour M., et al. Vancomycinresistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrob Agents Chemother 2005; 49:5046-50.
  • 33. Steenbergen J.N., Mohr J.F., Thorne G.M. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009;64:1130-8.
  • 34. Silverman J.A., Oliver N., Andrew T., Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45: 1799-1802.
  • 35. Rose W.E., Rybak M.J., Kaatz G.W. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing guidelines. Proceedings of 46th ICAAC 2006, A-630.
  • 36. Fischer A., Yang S., Bayer A.S., Vaezzadeh A.R., et al. Daptomycin-resistance mechanisms in clinically-derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. Proceedings of ICAAC 2010. C1-1441.
  • 37. Peleg A.Y., Mcalister A., Miyakis S., Ward D., et al. Genetic Evolution of Resistance to Daptomycin in Staphylococcus aureus. Proceedings of ICAAC 2010. C1- 1434.
  • 38. Mariani P.G., Sader H.S., Jones R.N. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58:481-3.
  • 39. Hayden M.K., Rezai K., Hayes R.A., Lolans K., Quinn J.P., Weinstein R.A. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285-7.
  • 40. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
  • 41. Kosowska-Shick K., Julian K., Brumbach A., et al. Characteristics of a S. aureus strain causing endocarditis which acquired VISA and daptomycinresistant phenotypes after daptomycin therapy. 46th Intersci Conf on Antimicrob Agents Chemother 2006, E-727.
  • 42. Sheth A., Carpenter C.F., Robinson-Dunn B. Reduced vancomycin susceptibility and daptomycin nonsusceptibility associated with treatment failure in 2 cases of MRSA bacteremia. 46th Intersci Conf on Antimicrob Agents Chemother 2006, C2-1159.
  • 43. Bell J.M., Walter L.J., Turnidge J.D., Jones R.N. Vancomycin hetero-resistance has a small but significant effect on the daptomycin minimum inhibitory concentration of Staphylococcus aureus. 46th Intersci Conf on Antimicrob Agents Chemother 2006, D-814.
  • 44. Munoz-Price L.S., Lolans K., Quinn J.P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005; 41:565-6.
  • 45. MсGrath D.M., Barbu E.M., Pasqualini R., et al. Resistance to daptomycin in vancomycin-resistant Enterococcus faecalisis associated with alterations of cell membrane potential and surface charge. Proceedings of ICAAC 2010. C1-078.
  • 46. Bowker K.E., Noel A.R., Macgowan A.P. The relationship between daptomycin free drug AUC/MIC, antibacterial effect and emergence of resistance in S.aureus. Proceedings of ICAAC 2009. A1-1271.
  • 47. Saleh-Mghir A., Muller-Serieys C., Massias L., Crémieux A.C. Combining high-dose daptomycin and rifampin is crucial for the treatment of methicillinresistant Staphylococcus aureus rabbit prosthetic joint infection. Proceedings of ICAAC 2010. B-698.
  • 48. Tsuji B.T., Rybak M.J. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agent Chemother 2005; 49:2735-45.
  • 49. Credito K., Lin G., Appelbaum P.C. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrobl Agent Chemother 2007; 51:1504-7.
  • 50. Dvorchik B.H., Brazier D., DeBruin M.F., Arbeit R.D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:1318- 23.
  • 51. Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245-9.
  • 52. Dvorchik B., Arbeit R.D., Chung J., Liu S., Knebel W., Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48:2799-807.
  • 53. Steenbergen J.N., Alder J., Thorne G.M. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55:283-8.
  • 54. Wise R., Gee T., Andrews J.M., Dvorchik B., Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46:31-3.
  • 55. Kullar R., Chin J.N., Parker D.,. Coplin W.M, Edwards D.J., Rybak M.J. Central nervous system penetration and pharmacokinetics of daptomycin. Proceedings of ICAAC 2010. A1-496.
  • 56. Dvorchik B., Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 2004; 44:612-20.
  • 57. Dvorchik B.H., Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45:48-56.
  • 58. Arbeit R.D., Maki D., Tally F.P., Campanaro E,. Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
  • 59. Cunha B.A., Eisenstein L.E., Hamid N.S.: Pacemakerinduced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/highdose daptomycin without toxicity. Heart Lung 2006; 35:207- 11.
  • 60. Fowler V.G., Jr, Boucher H.W., Corey G.R. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
  • 61. Canton R., Ruiz-Garbajosa P., Chaves R.L., Johnson A.P. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65:1126-36.
  • 62. Lamp K.C., Friedrich L.V. Clinical experience with daptomycin for the treatment of osteomyelitis in patients with post-therapy follow-up. Proceedings of 46th ICAAC 2006. L-1557.
  • 63. Forrest G., Donovan B., Lamp K., Friedrich L. Daptomycin use in patients with septic arthritis: postmarketing experience from CORE 2005. Proceedings of 46th ICAAC 2006, A-1556.
  • 64. Kozlov R., Edelstain M., Dekhnich A., et al. Etiology of nosocomial bacterial infections in Russia. Proceedings of 48th ICAAC. Washington, DC, 2008. K-4108.
  • 65. Nikulin A., Dekhnich A., Ivanchik N., Kozlov R. Susceptibility of Staphylococcus aureus in the community settings: first Russian surveillance. Proceedings of 19th ECCMID. Helsinki, 2009. P-1077.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились